|Videos|December 18, 2020
Optimizing Molecular Testing in Non-Small Cell Lung Cancer
Author(s)Cancer Network Staff
With the rise of precision oncology, genomic profiling is growing in its utility to support clinical decision making. Lung cancer experts can use this resource to guide therapy selection in NSCLC. Learning more about advancements in this space can improve patient outcomes and advance the field of precision oncology.
Advertisement
Discussion Topics:
- Recent Advances and Current Landscape of Molecular Testing in NSCLC: What can we expect from new NGS and Multiplex technologies?
- Emerging NSCLC Biomarkers of Disease: How can we most efficiently use molecular testing to make driver mutations more actionable in clinical practice?
- Panel Discussion of Real-World Case Studies of NSCLC Testing in Clinical Practice
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood-Based Lung Cancer Screening Tool Earns FDA Breakthrough Device Status
2
What Are The Biggest Misconceptions About CAR T Cells in Multiple Myeloma?
3
FDA Approves Iberdomide Combo in Relapsed/Refractory Multiple Myeloma
4
Defining the Objectives of an Analysis of Tarlatamab in Brain Metastases
5